超声乳化联合房角分离联合小梁切开术与超声乳化联合小梁切除术治疗晚期原发性闭角型青光眼合并白内障的两年结局:非劣效随机临床试验
这项在中国7家眼科中心开展的多中心非劣效随机临床试验纳入124例晚期原发性闭角型青光眼合并白内障患者,1:1随机接受超声乳化联合房角分离联合小梁切开术(phacogoniotomy)或超声乳化联合小梁切除术(phacotrabeculectomy)。2年随访时,phacogoniotomy组平均眼压降幅-25.6 mmHg,phacotrabeculectomy组-24.7 mmHg,组间差异-0.5 mmHg(97.5%CI -1.7至0.8),置信区间上限低于4 mmHg非劣效界值。完全成功和条件成功的组间差异均无统计学意义,作者认为phacogoniotomy可作为晚期PACG合并白内障患者phacotrabeculectomy的替代方案。
要点
- 2年随访时phacogoniotomy组平均眼压降幅-25.6 mmHg,phacotrabeculectomy组-24.7 mmHg,组间差异-0.5 mmHg(97.5%CI -1.7至0.8),非劣效成立。
- 完全成功组间差异-6.7%(95%CI -21.4%至8.8%,P=0.47),条件成功差异1.4%(95%CI -11.0%至14.3%,P=0.30),均无统计学意义。
- 抗青光眼药物使用数量中位数两组均为0(0),Hodges-Lehmann位置偏移估计0(95%CI 0,P=0.12)。
核心结论
- 2年随访时phacogoniotomy组平均眼压降幅非劣效于phacotrabeculectomy组,完全成功、条件成功及平均抗青光眼药物数量均未检测到差异。
- 作者认为这些发现支持phacogoniotomy作为晚期PACG合并白内障患者phacotrabeculectomy的替代方案。
研究设计与样本
- 多中心、非劣效、随机临床试验,在中国7家眼科中心开展,2021年5月31日启动,2年随访于2024年5月31日结束。
- 共纳入124例晚期PACG合并白内障患者(124眼),按1:1随机分配至phacogoniotomy组(65例,52.4%)或phacotrabeculectomy组(59例,47.6%)。
- 平均(SD)年龄66.4(8.6)岁,女性67例(54.0%),所有参与者均为中国人。
- phacogoniotomy组59例(90.7%)、phacotrabeculectomy组52例(88.1%)完成2年随访。
- 研究数据分析时间为2024年9月至2025年1月。
主要发现
- 主要结局:phacogoniotomy组平均(SD)眼压降幅-25.6(10.2)mmHg,phacotrabeculectomy组-24.7(9.4)mmHg;组间均值差-0.5 mmHg(97.5%CI -1.7至0.8 mmHg,P=0.42),置信区间上限低于4 mmHg非劣效界值。
- 完全成功:phacogoniotomy组 vs phacotrabeculectomy组均值差-6.7%(95%CI -21.4%至8.8%,P=0.47),未达统计学显著。
- 条件成功:phacogoniotomy组 vs phacotrabeculectomy组均值差1.4%(95%CI -11.0%至14.3%,P=0.30),未达统计学显著。
- 抗青光眼药物数量中位数(IQR):phacogoniotomy组0(0) vs phacotrabeculectomy组0(0);Hodges-Lehmann位置偏移估计0(95%CI 0,P=0.12);均值差0.13(95%CI -0.36至0.63,P=0.60)。
关键数值与推荐
- 主要结局指标为非劣效界值4 mmHg的眼压降幅,phacogoniotomy组相对phacotrabeculectomy组的组间均值差-0.5 mmHg(97.5%CI -1.7至0.8 mmHg)。
- 完全成功组间均值差-6.7%(95%CI -21.4%至8.8%,P=0.47);条件成功组间均值差1.4%(95%CI -11.0%至14.3%,P=0.30)。
- 抗青光眼药物数量中位数均为0(0),Hodges-Lehmann位置偏移估计0(95%CI 0,P=0.12)。
临床怎么用
- 作者认为这些发现支持phacogoniotomy作为晚期PACG合并白内障患者phacotrabeculectomy的替代方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Intraocular pressure (IOP) reduction with phacogoniotomy (phacoemulsification plus goniosynechialysis plus goniotomy) was not less than that of phacotrabeculectomy for advanced primary angle-closure glaucoma (PACG) with cataract at 1-year follow-up, but longer-term outcomes are needed. OBJECTIVE: To investigate if phacogoniotomy is noninferior to phacotrabeculectomy for advanced PACG with cataract at 2 years. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, noninferiority, randomized clinical trial took place in 7 ophthalmology centers in China. The trial started May 31, 2021, and 2-year follow-up ended May 31, 2024. Included in this analysis were patients with advanced PACG and cataract. Study data were analyzed from September 2024 to January 2025. INTERVENTIONS: Random assignment (1:1) to phacogoniotomy or phacotrabeculectomy. MAIN OUTCOMES AND MEASURES: The primary outcome measure was reduction in IOP from baseline to the 2-year visit with a noninferiority margin of 4 mm Hg. RESULTS: A total of 124 participants (124 eyes) were randomized (mean [SD] age, 66.4 [8.6] years; 67 female [54.0%]), 65 (52.4%) to the phacogoniotomy group and 59 (47.6%) to the phacotrabeculectomy group. A total of 59 patients (90.7%) in the phacogoniotomy group and 52 patients (88.1%) in the phacotrabeculectomy group completed 2-year visits. All participants were Chinese. Mean (SD) IOP reduction was -25.6 (10.2) mm Hg and -24.7 (9.4) mm Hg in the phacogoniotomy and phacotrabeculectomy groups, respectively, and the upper boundary of the CI for difference in change between groups was lower than the 4-mm Hg noninferiority margin (mean difference, -0.5 mm Hg; 97.5% CI, -1.7 mm Hg to 0.8 mm Hg; P = .42). The mean difference for complete success for phacogoniotomy vs phacotrabeculectomy was -6.7% (95% CI, -21.4% to 8.8%; P = .47) and for qualified success was 1.4% (95% CI, -11.0% to 14.3%, P = .30). Median (IQR) number of antiglaucomatous medication was 0 (0) vs 0 (0; Hodges-Lehmann estimate of location shift, 0; 95% CI, 0; P =.12) with phacogoniotomy vs phacotrabeculectomy, respectively (mean difference, 0.13; 95% CI, -0.36 to 0.63; P = .60). CONCLUSIONS AND RELEVANCE: Mean IOP reduction with phacogoniotomy was noninferior to phacotrabeculectomy for advanced PACG and cataract at 2-year follow-up with no differences detected in complete or qualified success or mean number of antiglaucomatous medications. These findings support phacogoniotomy as an alternative to phacotrabeculectomy for patients with advanced PACG and cataract. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04878458.
引用
- Song Y, Fan S, Tang L, et al. Two-Year Outcomes of Phacogoniotomy vs Phacotrabeculectomy for Advanced Primary Angle-Closure Glaucoma With Cataract: A Noninferiority Randomized Clinical Trial. JAMA Ophthalmol. 2025. PMID: 40244620. doi:10.1001/jamaophthalmol.2025.0685
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。